Novo Nordisk, Europe’s leading pharmaceutical company, has injected new life into the competitive weight-loss drug market with promising trial results for its next-generation obesity drug, amycretin. The drug, delivered via weekly subcutaneous injection, demonstrated impressive weight loss figures in a Phase 1b/2a trial, sparking a significant surge in Novo Nordisk’s share price. Patients receiving the highest dose of 20 milligrams achieved an estimated 22.1% weight reduction over 36 weeks, rivaling the performance of Eli Lilly’s leading obesity treatment, Mounjaro (tirzepatide), which achieved 22.5% weight loss over a longer 72-week period. While Lilly’s experimental drug, retatrutide, has shown even greater weight loss potential at 24.4% over 48 weeks, amycretin’s positive results signal Novo Nordisk’s commitment to maintaining its position in this rapidly expanding market.
The news of amycretin’s success prompted a significant rally in Novo Nordisk’s shares, which jumped as much as 14% before closing 7.13% higher. This positive market reaction stands in contrast to the company’s recent performance, with shares down 14% over the past year following disappointing results for another experimental obesity drug, CagriSema. The positive results for amycretin represent a significant rebound for Novo Nordisk, reaffirming their commitment to innovation in the weight-loss arena. This development also intensifies the competition with Eli Lilly, whose share price initially dipped before recovering to close with a gain. The fluctuating stock prices reflect the high stakes and intense competition within the lucrative obesity treatment market.
Amycretin is positioned as a key player in Novo Nordisk’s weight-loss pipeline, especially with the patent for its current blockbuster drug, Wegovy, set to expire in the early 2030s. The drug operates by mimicking both the GLP-1 (glucagon-like peptide-1) hormone and amylin, a hormone involved in satiety and blood sugar regulation. This dual-action approach distinguishes it from Wegovy, which focuses solely on GLP-1, and Ozempic, another Novo Nordisk drug specializing in diabetes treatment. The combination of GLP-1 and amylin agonists allows amycretin to potentially offer enhanced weight loss benefits and improved glycemic control.
The clinical trial involved 125 participants and tested different dosages of amycretin administered weekly. The results demonstrated a dose-dependent weight loss, with increasing reductions observed at higher doses. Alongside the 22.1% weight loss with the 20-milligram dose, the trial also reported 16.2% weight loss with 5 milligrams over 28 weeks and 9.7% weight loss with 1.25 milligrams over 20 weeks. While gastrointestinal side effects were reported, they were predominantly mild to moderate, further bolstering the drug’s potential. The positive outcome of this trial paves the way for further clinical development of amycretin for adults struggling with overweight or obesity.
Despite the promising results for amycretin, Novo Nordisk faces increasing pressure from competitors, particularly Eli Lilly, who are also developing next-generation weight-loss treatments. A significant area of focus is the development of oral treatments, which offer improved convenience and lower manufacturing costs compared to injectables. Eli Lilly’s experimental oral drug, orforglipron, has shown promising results in mid-stage trials with a 14.7% weight reduction over 36 weeks and is anticipated to receive regulatory approval as early as this year. This development poses a significant challenge to Novo Nordisk, highlighting the importance of offering diverse treatment options to cater to patient preferences and market demands.
Novo Nordisk is also exploring oral formulations of its existing and experimental drugs. While the company is developing an oral version of amycretin, early trials, albeit demonstrating a 13.1% weight loss, were hampered by side effects. Similarly, trials for an oral formulation of semaglutide, the active ingredient in Wegovy and Ozempic, have shown an average weight loss of 15% over 68 weeks. The pursuit of oral formulations underscores the pharmaceutical industry’s recognition of patient preference for this delivery method, yet balancing efficacy with manageable side effects remains a critical challenge in ongoing drug development. The competition in this sector is fierce, and the race to develop safe, effective, and convenient weight-loss treatments is constantly evolving.
